New Janssen Phase 3 Data in Patients with Moderately to Severely Active Rheumatoid Arthritis Shows Sirukumab Significantly Inhibited Radiographic Progression and Improves Signs and Symptoms of Disease
London, United Kingdom, 8 June, 2016 – Janssen Research & Development, LLC (Janssen) announced today results from a pivotal Phase 3 study evaluating…